Home
Statistics
How It Works
Login
Register
Keyword Connections
-
clostridium
Keywords
Connection Type
Connection
Journals
Toxins
biotechnology advances
Research Groups
No Research Group Connected
Bibliographies
[1]
Consolidated bio-saccharification: Leading lignocellulose bioconversion into the real world.
[2]
recent developments of the synthetic biology toolkit for clostridium
[3]
a combination of extreme environmental conditions favor the prevalence of endospore-forming firmicutes
[4]
treating clostridium difficile infections: should fecal microbiota transplantation be reclassified from investigational drug to human tissue?
[5]
presence of toxic microbial metabolites in table olives
[6]
Vaccine Production to Protect Animals Against Pathogenic Clostridia.
[7]
Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile
[8]
Pomegranate extract specifically inhibits Clostridium difficile growth and toxin production without disturbing the beneficial bacteria in vitro
[9]
Nationwide surveillance of ribotypes and antimicrobial susceptibilities of toxigenic Clostridium difficile isolates with an emphasis on reduced doxycycline and tigecycline susceptibilities among ribotype 078 lineage isolates in Taiwan
[10]
Molecular epidemiology of Clostridium difficile in two tertiary care hospitals in Shandong Province, China
[11]
Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis
[12]
Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value
[13]
National antimicrobial stewardship and fluoroquinolone-resistant Clostridium difficile in China
[14]
An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes
[15]
Diagnosing Clostridium difficile-associated diarrhea using enzyme immunoassay: the clinical significance of toxin negativity in glutamate dehydrogenase-positive patients
[16]
Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm
[17]
Community-acquired Clostridium difficile infection: an increasing public health threat
[18]
Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
[19]
Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile
[20]
Pomegranate extract specifically inhibits Clostridium difficile growth and toxin production without disturbing the beneficial bacteria in vitro
[21]
Nationwide surveillance of ribotypes and antimicrobial susceptibilities of toxigenic Clostridium difficile isolates with an emphasis on reduced doxycycline and tigecycline susceptibilities among ribotype 078 lineage isolates in Taiwan
[22]
Molecular epidemiology of Clostridium difficile in two tertiary care hospitals in Shandong Province, China
[23]
Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis
[24]
Endogenous Clostridium perfringens Panophthalmitis with Potential Entry Port from Diverticulitis Exacerbated by Proliferative Diabetic Retinopathy
[25]
Decreased Clostridium Abundance after Electroconvulsive Therapy in the Gut Microbiota of a Patient with Schizophrenia
[26]
Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value
[27]
National antimicrobial stewardship and fluoroquinolone-resistant Clostridium difficile in China
[28]
An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes
[29]
Diagnosing Clostridium difficile-associated diarrhea using enzyme immunoassay: the clinical significance of toxin negativity in glutamate dehydrogenase-positive patients
[30]
Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm
[31]
Community-acquired Clostridium difficile infection: an increasing public health threat
[32]
Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
[33]
A Novel Quantitative Sampling Technique for Detection and Monitoring of Clostridium difficile Contamination in the Clinical Environment.
[34]
Integrated genomic epidemiology and phenotypic profiling of Clostridium difficile across intra-hospital and community populations in Colombia
[35]
σ <sup>54</sup> (σ <sup>L</sup> ) plays a central role in carbon metabolism in the industrially relevant Clostridium beijerinckii
[36]
Correction to: Fed-batch acetone-butanol-ethanol fermentation using immobilized Clostridium acetobutylicum in calcium alginate beads (Korean Journal of Chemical Engineering, (2019), 36, 6, (909-913), 10.1007/s11814-018-0232-z)
[37]
Analyses of miRNA in the ileum of diarrheic piglets caused by Clostridium perfringens type C.
[38]
Clostridium perfringens enterotoxin-based protein engineering for the vaccine design and delivery system
[39]
Growth of Clostridium perfringens in cooked chicken during cooling: One-step dynamic inverse analysis, sensitivity analysis, and Markov Chain Monte Carlo simulation
[40]
Clostridium botulinum Spores Found in Honey from Small Apiaries in Poland
[41]
Implementation of a Checklist to Reduce False-Positive Testing in Hospital-Acquired Clostridium Difficile Infection.
[42]
Erratum: Correction for Kraft et al., "A Laboratory Medicine Best Practices Systematic Review and Meta-analysis of Nucleic Acid Amplification Tests (NAATs) and Algorithms Including NAATs for the Diagnosis of Clostridioides (Clostridium) difficile in Adults" (Clinical microbiology reviews (2019) 32 3 PII: e00128-19)
[43]
Collagenase Clostridium Histolyticum: A Review in Peyronie's Disease.
[44]
Clostridium difficile: Is it a new food-borne pathogen?
[45]
Use of fluorescent CTP1L endolysin cell wall-binding domain to study the evolution of Clostridium tyrobutyricum during cheese ripening.
[46]
Effect of detoxification methods on ABE production from corn stover hydrolysate by Clostridium acetobutylicum CICC 8016.
[47]
Flooding-Associated Soft Rot of Sweetpotato Storage Roots Caused by Distinct Clostridium Isolates
[48]
Detection of Clostridium perfringens toxinotypes, enteropathogenic e. coli, rota and corona viruses in the intestine of neonatal goat kids by molecular techniques
[49]
Clostridium cellulovorans metabolism of cellulose as studied by comparative proteomic approach.
[50]
Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance
[51]
Butanol production from cellulosic material by anaerobic co-culture of white-rot fungus Phlebia and bacterium Clostridium in consolidated bioprocessing.
[52]
Thermodynamic Analysis of Glycolysis in Clostridium thermocellum and Thermoanaerobacterium saccharolyticum Using C and H Tracers.
[53]
The tcdA negative and tcdB positive Clostridium difficile ST81 clone exhibits high-level fluoroquinolone resistance: a multi-center study in Beijing, China.
[54]
Evaluation of factors influencing the growth of non-toxigenic Clostridium botulinum type E and Clostridium sp. in high-pressure processed and conditioned tender coconut water from Thailand
[55]
Systematic Review of Intestinal Microbiota Transplantation (Fecal Bacteriotherapy) for Recurrent Clostridium difficile Infection
[56]
Bacterial Diarrhea in HIV-Infected Patients: Why Clostridium difficile, and Why Now?
[57]
Clostridium difficile infection in fever patients with gynecological malignancies
[58]
Staggered and Tapered Antibiotic Withdrawal With Administration of Kefir for Recurrent Clostridium difficile Infection
[59]
Antimicrobial Resistance Gene Acquisition and Depletion Following Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection
[60]
Differences of the Fecal Microflora With Clostridium difficile Therapies
[61]
Clostridium difficile Infection in Long-term Care Facilities: A Call to Action for Antimicrobial Stewardship
[62]
Prospective assessment of Clostridioides (formerly Clostridium) difficile colonization and acquisition in hematopoietic stem cell transplant patients
[63]
Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
[64]
Risk factors for Clostridium difficile-associated diarrhoea in HIV-infected patients
[65]
Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens.
[66]
Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections
[67]
Epidemiology of community-acquired Clostridium difficile-associated diarrhea
[68]
A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+)
[69]
Fecal Microbiota Transplant for Relapsing Clostridium difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study
[70]
Early Fecal Microbiota Transplantation Improves Survival in Severe Clostridium difficile Infections
[71]
Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study
[72]
Evolving Insights Into the Epidemiology and Control of Clostridium difficile in Hospitals
[73]
Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial
[74]
Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection
[75]
A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile–associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation
[76]
Comparison of clindamycin, rifampin, tetracycline, metronidazole, and penicillin for efficacy in prevention of experimental gas gangrene due to Clostridium perfringens
[77]
Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection
[78]
Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens
[79]
Patient Attitudes Toward the Use of Fecal Microbiota Transplantation in the Treatment of Recurrent Clostridium difficile Infection
[80]
Prevalence and Pathogenicity of Clostridium difficile in Hospitalized Patients: A French Multicenter Study
[81]
Factors affecting initiation of growth of Clostridium botulinum
[82]
Renal Failure and Leukocytosis Are Predictors of a Complicated Course of Clostridium difficile Infection if Measured on Day of Diagnosis
[83]
Pathway to Prevention of Nosocomial Clostridium difficile Infection
[84]
Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial
[85]
Duodenal infusion of donor feces for recurrent Clostridium difficile
[86]
Risk factors for Clostridium difficile toxin-associated diarrhea
[87]
John G. Bartlett: Contributions to the Discovery of Clostridium difficile Antibiotic-Associated Diarrhea
[88]
Prevention of Clostridium difficile Infection With Probiotics
[89]
Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): Characterization, Manufacture, Mechanisms of Action, and Quality Control of a Specific Probiotic Combination for Primary Prevention of Clostridium difficile Infection
[90]
Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
[91]
Epidemiology and outcome of Clostridium difficile infection and diarrhea in HIV infected inpatients
[92]
Diarrhea and Clostridium difficile Infection in Latin American Patients with AIDS
[93]
Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection
[94]
Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection
[95]
Clostridium difficile-associated diarrhea in HIV-infected patients: epidemiology and risk factors
[96]
Epidemiology of Community-Acquired Clostridium difficile-Associated Diarrhea
[97]
Comparison of Clindamycin, Rifampin, Tetracycline, Metronidazole, and Penicillin for Efficacy in Prevention of Experimental Gas Gangrene Due to Clostridium perfringens
[98]
The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida
[99]
Leaping Forward in the Treatment of Clostridium Difficile Infection: Update in 2015
[100]
clostridium perfringens e a enterite necrótica em frangos: principais fatores de virulência, genéticos e moleculares
[101]
pseudomembranous colitis: not always caused by clostridium difficile